Resmetirom丨CAS 920509-32-6

Resmetirom丨CAS 920509-32-6
Product Introduction:
Catalog No.: SS130025
CAS No.: 920509-32-6
Assay (calculated on the dried basis): 98.0%~102.0%
Product Name: Resmetirom
Molecular Formula: C17H12Cl2N6O4
Molecular Weight: 435.22
Synonym(s): MGL-3196
Send Inquiry
Technical Parameters
Description

Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of resmetirom丨cas 920509-32-6 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.

 

Specifications

 

Appearance: White to yellow or orange powder
Assay (calculated on the dried basis): 98.0%~102.0%
Solubility: Freely soluble in dimethyl sulfoxide, slightly soluble in ethanol, practically insoluble in water
Appearance of solution: The solution is clear and not more intensely colored than reference solution Y6
Identification: IR: The infrared absorption spectrum of the sample shall be consistent with that of the reference substance.
HPLC: The retention time of the major peak of the sample solution corresponds to that of the standard solution, as obtained in the Assay.
Heavy metal: 20ppm max
Loss on drying: 0.5% max
Residue on ignition: 0.1% max
Related substances: Single impurity: 0.10% max
Total impurities: 0.50% max
Residual solvent: Acetone: 0.50% max
Ethanol: 0.50% max
Methyl isobutyl ketone: 0.45% max
N,N-Dimethylacetamide: 0.109% max
Microbial Contamination: Total Aerobic Microbial Count: 10³ CFU/g max
Total Combined Yeasts/Molds Count: 10² CFU/g max
Escherichia coli: cannot be detected

 

 

 

Applications

 

1. Treatment of NASH (Non-Alcoholic Steatohepatitis)

Primary application of Resmetirom.

NASH is a severe form of non-alcoholic fatty liver disease (NAFLD) characterized by fat accumulation, inflammation, and fibrosis.

Resmetirom activates THR-β in the liver, promoting lipid metabolism and reducing hepatic fat content, inflammation, and fibrosis without the systemic side effects of traditional thyroid hormones.

2. Dyslipidemia and Hypercholesterolemia

Resmetirom lowers LDL-C, triglycerides, and apolipoprotein B by enhancing hepatic uptake and clearance of cholesterol and triglyceride-rich particles.

Useful in familial hypercholesterolemia, mixed dyslipidemia, and atherosclerosis prevention.

3. Metabolic Syndrome and Obesity

By improving liver function and lipid profiles, Resmetirom shows potential in broader metabolic disorders.

Supports weight management indirectly through lipid modulation.

4. Investigational Use in Cardiovascular Disease

Due to its lipid-lowering effect and impact on hepatic steatosis, Resmetirom is being explored as a cardiometabolic health promoter.

Benefits

 

✅ Selective THR-β Agonism

Unlike natural thyroid hormones that act on both THR-α and THR-β, Resmetirom selectively activates THR-β, which is predominantly expressed in liver tissue.

This minimizes cardiac and skeletal muscle side effects often seen with thyroid hormone therapy.

✅ Non-Hormonal Side Effects

Does not significantly affect heart rate or bone density, making it safer for long-term use compared to T3 or T4 derivatives.

✅ Liver-Targeted Action

Optimized for hepatic distribution, making it ideal for liver-centric conditions like NAFLD and NASH.

✅ Clinically Proven Fat Reduction

Phase 2 and 3 clinical trials have demonstrated:

~30% relative reduction in liver fat (MRI-PDFF)

Reduction in fibrosis biomarkers

Improvement in liver enzymes (ALT, AST)

✅ Orally Bioavailable

Resmetirom is taken orally once daily, offering patient compliance advantages over injectable or invasive treatments.

✅ Potential Disease-Modifying Effects

Not only improves biomarkers, but potentially halts or reverses disease progression in NASH and related liver pathologies.

Conclusion

Resmetirom (CAS 920509-32-6) represents a new class of liver-targeted metabolic modulators that address the growing burden of non-alcoholic steatohepatitis (NASH) and dyslipidemia. Its selective action on THR-β makes it a safe and effective therapeutic candidate with broad potential across cardiometabolic disorders. If approved, it may be a game-changer in hepatology and metabolic medicine.

 

 

Send Inquiry
Beyond Your Expectation
From Science to Life with LEAPChem
contact us